Skip to main content
. 2020 Jun 13;11(6):590. doi: 10.3390/mi11060590

Figure 8.

Figure 8

Comparison of the results obtained from the impedance sensor and the Adenosine triphosphate (ATP) assay. The serine/threonine-protein kinase B-Raf (BRAF) inhibitor vemurafenib was applied to 2D mutated melanoma in vitro models. (A) Fluorescence images of the melanoma cells with and without treatment with vemurafenib. (B) Normalized concentration-response curves, (C) efficacy plotted over time, and (D) potency plotted over time obtained from the impedance sensor (black line) and ATP assay (gray line). Reprinted from Seidel et al. [73] with permission from Elsevier.